242 related articles for article (PubMed ID: 31553054)
21. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
[TBL] [Abstract][Full Text] [Related]
22. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
[TBL] [Abstract][Full Text] [Related]
24. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
25. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report.
Abdallah N; Nagasaka M; Chowdhury T; Raval K; Hotaling J; Sukari A
Oral Oncol; 2019 Dec; 99():104350. PubMed ID: 31277904
[TBL] [Abstract][Full Text] [Related]
26. Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Grisic AM; Xiong W; Tanneau L; Jönsson S; Friberg LE; Karlsson MO; Dai H; Zheng J; Girard P; Khandelwal A
Clin Cancer Res; 2022 Apr; 28(7):1363-1371. PubMed ID: 34921021
[TBL] [Abstract][Full Text] [Related]
27. Which place for avelumab in the management of urothelial carcinoma?
Larroquette M; Gross-Goupil M; Daste A; Robert G; Ravaud A; Domblides C
Expert Opin Biol Ther; 2019 Sep; 19(9):863-870. PubMed ID: 31286802
[No Abstract] [Full Text] [Related]
28. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
29. Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review.
Sharma AN; Shah KS; Sharma AA; Yu SS
Dermatol Surg; 2024 May; 50(5):407-411. PubMed ID: 38349855
[TBL] [Abstract][Full Text] [Related]
30. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort.
Levy S; Aarts MJB; Eskens FALM; Keymeulen KBMI; Been LB; Grünhagen D; van Akkooi A; Jalving M; Tesselaar MET
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948651
[TBL] [Abstract][Full Text] [Related]
31. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
D'Angelo SP; Hunger M; Brohl AS; Nghiem P; Bhatia S; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Schlichting M; Hennessy MH; Bharmal M
Cancer Immunol Immunother; 2019 Apr; 68(4):609-618. PubMed ID: 30721341
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
33. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
Munhoz RR; Cayol F; Corrales L; Gerson R; Tilli M; Barreto EO; Sánchez Castillo JO; Schmerling RA; Cinat G
Cancer Immunol Immunother; 2021 Apr; 70(4):1031-1036. PubMed ID: 33104838
[TBL] [Abstract][Full Text] [Related]
34. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
35. Successful rechallenge with avelumab in Merkel cell carcinoma.
Amiot M; Brunet Possenti F; Lebbé C; Baroudjian B
Eur J Cancer; 2021 Aug; 153():96-97. PubMed ID: 34153719
[No Abstract] [Full Text] [Related]
36. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma.
Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934
[No Abstract] [Full Text] [Related]
37. Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab.
Shibayama Y; Kameda H; Ota S; Tsuchida K; Cho KY; Nakamura A; Miyoshi H; Atsumi T
J Diabetes Investig; 2019 Sep; 10(5):1385-1387. PubMed ID: 30738003
[TBL] [Abstract][Full Text] [Related]
38. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Goldstein DA; Ratain MJ; Saltz LB
JAMA Oncol; 2020 Nov; 6(11):1694-1695. PubMed ID: 32459313
[No Abstract] [Full Text] [Related]
39. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
[TBL] [Abstract][Full Text] [Related]
40. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
